Murali Chintagumpala1, Sandrah P Eckel1, Mark Krailo1, Michael Morris1, Adekunle Adesina1, Roger Packer1, Ching Lau1, Amar Gajjar1. 1. Texas Children's Cancer and Hematology Centers, Department of Pathology, Baylor College of Medicine, Houston, Texas (M.C., A.A., C.L.); Department of Preventive Medicine, University of Southern California, Los Angeles, California (S.P.E., M.K.); University of Texas Southwestern Medical Center, Dallas, Texas (M.M.); Children's National Medical Center, Washington DC (R.P.); St Jude Children's Research Hospital, Memphis, Tennessee (A.G.).
Abstract
BACKGROUND: This study was initiated to test the feasibility and toxicity of a regimen that alternates the administration of weekly carboplatin and vincristine with temozolomide in the management of children with progressive and/or symptomatic low-grade glioma. METHODS: Eligible children received a 10-week induction regimen followed by six 10-week cycles of maintenance chemotherapy. Feasibility was evaluated with short-term and long-term endpoints. Short-term feasibility was evaluated by the ability to complete induction and 1 maintenance cycle in 24 weeks without >25% reduction in either carboplatin or temozolomide. Long-term feasibility was evaluated by the ability to administer induction and 4 maintenance cycles within 60 weeks without >25% reduction in either carboplatin or temozolomide. Efficacy was assessed by response to initial chemotherapy and 5-year event-free survival. Initial pathology was reviewed centrally. RESULTS: Sixty-six patients were enrolled on the study. It was feasible to deliver the regimen, and toxicity was acceptable. The only significant toxicities were hematologic. Both the short-term and long-term feasibility endpoints were met. The short-term feasibility success rate was 87% (95% CI: 77%-96%) and the long-term feasibility success rate was 79% (95% CI: 68%-90%). The 5-year event-free survival was 46% (95% CI: 33%-58%) and the 5-year survival was 87% (95% CI: 75%-93%). CONCLUSION: It was feasible to deliver the combination of weekly carboplatin and vincristine alternating with temozolomide to children with progressive/symptomatic low-grade glioma with acceptable toxicities. This combination appears to be effective in delaying progression. Further trials are needed to establish the relative efficacy of this regimen compared with other regimens in use.
BACKGROUND: This study was initiated to test the feasibility and toxicity of a regimen that alternates the administration of weekly carboplatin and vincristine with temozolomide in the management of children with progressive and/or symptomatic low-grade glioma. METHODS: Eligible children received a 10-week induction regimen followed by six 10-week cycles of maintenance chemotherapy. Feasibility was evaluated with short-term and long-term endpoints. Short-term feasibility was evaluated by the ability to complete induction and 1 maintenance cycle in 24 weeks without >25% reduction in either carboplatin or temozolomide. Long-term feasibility was evaluated by the ability to administer induction and 4 maintenance cycles within 60 weeks without >25% reduction in either carboplatin or temozolomide. Efficacy was assessed by response to initial chemotherapy and 5-year event-free survival. Initial pathology was reviewed centrally. RESULTS: Sixty-six patients were enrolled on the study. It was feasible to deliver the regimen, and toxicity was acceptable. The only significant toxicities were hematologic. Both the short-term and long-term feasibility endpoints were met. The short-term feasibility success rate was 87% (95% CI: 77%-96%) and the long-term feasibility success rate was 79% (95% CI: 68%-90%). The 5-year event-free survival was 46% (95% CI: 33%-58%) and the 5-year survival was 87% (95% CI: 75%-93%). CONCLUSION: It was feasible to deliver the combination of weekly carboplatin and vincristine alternating with temozolomide to children with progressive/symptomatic low-grade glioma with acceptable toxicities. This combination appears to be effective in delaying progression. Further trials are needed to establish the relative efficacy of this regimen compared with other regimens in use.
Authors: Maura Massimino; Filippo Spreafico; Graziella Cefalo; Riccardo Riccardi; John David Tesoro-Tess; Lorenza Gandola; Daria Riva; Antonio Ruggiero; Laura Valentini; Elena Mazza; Lorenzo Genitori; Concezio Di Rocco; Piera Navarria; Michela Casanova; Andrea Ferrari; Roberto Luksch; Monica Terenziani; Maria Rosa Balestrini; Cesare Colosimo; Franca Fossati-Bellani Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: Tim Forshew; Ruth G Tatevossian; Andrew R J Lawson; Jing Ma; Geoff Neale; Babatunji W Ogunkolade; Tania A Jones; Johan Aarum; James Dalton; Simon Bailey; Tracy Chaplin; Rowena L Carter; Amar Gajjar; Alberto Broniscer; Bryan D Young; David W Ellison; Denise Sheer Journal: J Pathol Date: 2009-06 Impact factor: 7.996
Authors: Angela J Sievert; Eric M Jackson; Xiaowu Gai; Hakon Hakonarson; Alexander R Judkins; Adam C Resnick; Leslie N Sutton; Phillip B Storm; Tamim H Shaikh; Jaclyn A Biegel Journal: Brain Pathol Date: 2008-10-21 Impact factor: 6.508
Authors: Roger J Packer; Regina Jakacki; Marianna Horn; Brian Rood; Gilbert Vezina; Tobey MacDonald; Michael J Fisher; Bruce Cohen Journal: Pediatr Blood Cancer Date: 2009-07 Impact factor: 3.167
Authors: K Jacob; S Albrecht; C Sollier; D Faury; E Sader; A Montpetit; D Serre; P Hauser; M Garami; L Bognar; Z Hanzely; J L Montes; J Atkinson; J-P Farmer; E Bouffet; C Hawkins; U Tabori; N Jabado Journal: Br J Cancer Date: 2009-07-14 Impact factor: 7.640
Authors: Anandani Nellan; Erin Wright; Kristen Campbell; Kurtis D Davies; Andrew M Donson; Vladimir Amani; Alexis Judd; Molly S Hemenway; Jennifer Raybin; Nicholas K Foreman; Sarah Rush; Kathleen Dorris Journal: J Neurooncol Date: 2020-06-06 Impact factor: 4.130
Authors: Santhosh A Upadhyaya; Giles W Robinson; Julie H Harreld; Paul D Klimo; Mary Ellen Hoehn; Brent A Orr; Ibrahim A Qaddoumi Journal: Childs Nerv Syst Date: 2018-02-01 Impact factor: 1.475
Authors: Liana Nobre; Michal Zapotocky; Vijay Ramaswamy; Scott Ryall; Julie Bennett; Daniel Alderete; Julia Balaguer Guill; Lorena Baroni; Ute Bartels; Abhishek Bavle; Miriam Bornhorst; Daniel R Boue; Adela Canete; Murali Chintagumpala; Scott L Coven; Ofelia Cruz; Sonika Dahiya; Peter Dirks; Ira J Dunkel; David Eisenstat; Cecile Faure Conter; Elizabeth Finch; Jonathan L Finlay; Didier Frappaz; Maria Luisa Garre; Karen Gauvain; Anne Grete Bechensteen; Jordan R Hansford; Inga Harting; Peter Hauser; Lili-Naz Hazrati; Annie Huang; Sarah G Injac; Valentina Iurilli; Matthias Karajannis; Gurcharanjeet Kaur; Martin Kyncl; Lenka Krskova; Normand Laperriere; Valerie Larouche; Alvaro Lassaletta; Sarah Leary; Frank Lin; Samantha Mascelli; Tara McKeown; Till Milde; Andres Morales La Madrid; Giovanni Morana; Helena Morse; Naureen Mushtaq; Diana S Osorio; Roger Packer; Zdenek Pavelka; Eduardo Quiroga-Cantero; James Rutka; Magnus Sabel; Duarte Salgado; Palma Solano; Jaroslav Sterba; Jack Su; David Sumerauer; Michael D Taylor; Helen Toledano; Derek S Tsang; Mariana Valente Fernandes; Frank van Landeghem; Cornelis M van Tilburg; Bev Wilson; Olaf Witt; Josef Zamecnik; Eric Bouffet; Cynthia Hawkins; Uri Tabori Journal: JCO Precis Oncol Date: 2020-05-20
Authors: Roger J Packer; Stephan Pfister; Eric Bouffet; Robert Avery; Pratiti Bandopadhayay; Miriam Bornhorst; Daniel C Bowers; David Ellison; Jason Fangusaro; Nicholas Foreman; Maryam Fouladi; Amar Gajjar; Daphne Haas-Kogan; Cynthia Hawkins; Cheng-Ying Ho; Eugene Hwang; Nada Jabado; Lindsay B Kilburn; Alvaro Lassaletta; Keith L Ligon; Maura Massimino; Schouten-van Meeteren; Sabine Mueller; Theo Nicolaides; Giorgio Perilongo; Uri Tabori; Gilbert Vezina; Katherine Warren; Olaf Witt; Yuan Zhu; David T Jones; Mark Kieran Journal: Neuro Oncol Date: 2017-06-01 Impact factor: 12.300
Authors: David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Julio C Furlan; Jefferson R Wilson; Eric M Massicotte; Arjun Sahgal; Michael G Fehlings Journal: Neuro Oncol Date: 2022-01-05 Impact factor: 13.029
Authors: Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening Journal: Cochrane Database Syst Rev Date: 2019-03-11